LAUSR

The current standard therapy of epithelial ovarian cancer (EOC) is the combination of surgery and multi-agent chemotherapy with/without adding targeted therapy. After treatment, response rate is high and nearly all patients can achieve complete remission, even though they are advanced diseases; however, the majority of patients will relapse and subsequently die of diseases within several years after initial treatment. When treatment options are limited, there is the urgent need for new novel therapeutic approaches for precise cancer control. The development of chemo-resistance and evading of the anti-cancer immune response may be one of the important causes contributing to the therapeutic failure, and therefore, it represent a paradigm shift in cancer research. An individual's immune response and interaction with EOC cells might be one of key factors for cancer treatment. There are many interventions, including targeting certain-type immunogenic EOC-associated antigens, immune checkpoint blockade, and adoptive cellular therapy, which present a profound opportunity to revolutionize EOC treatment. This review will encompass the interaction between EOC and immune system and highlight recent data regarding the research of immunotherapy in EOC.